INVO Fertility, Inc. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
INVO Fertility reported Q2 2026 revenue of $2.175M (up 17% YoY from $1.864M), driven by full-quarter contribution from February 2026 Family Beginnings acquisition and organic growth. Clinic-Level Adjusted EBITDA was $333K in Q2 2026 vs. $164K in Q1 2026. In June 2026, INVO acquired remaining ownership interests in Birmingham clinic, converting from joint venture to wholly-owned subsidiary. Net income was $0.9M (vs. $3.6M loss YoY), but included $2.5M non-cash gain on Birmingham remeasurement; Adjusted EBITDA remained negative at $(1.0M). Cash position improved to $3.7M vs. $2.1M at year-end 2025.
Why this rating
For a $2.2M market-cap company, $2.2M quarterly revenue is substantial; clinic profitability at scale and improved cash position are meaningful. Growth trajectory and M&A execution matter, but small absolute scale and negative corporate-level EBITDA limit significance.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.